CliffBio
small molecule

EDARBI

AZILSARTAN KAMEDOXOMIL

Loss of exclusivityMarch 2028latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameEDARBI
Active ingredientAZILSARTAN KAMEDOXOMIL
StrengthEQ 80MG MEDOXOMIL
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2011
Marketing statusRX

Listed patents

PatentExpiresType
9066936March 2028product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EDARBI patent cliff — loss of exclusivity March 2028 | CliffBio